Meike Fünderich

Meike Fünderich

Auto-generated profile, based on publicly available information

Meike Fünderich

Department of Internal Medicine, Universities of Giessen and Marburg Lung Center (UGMLC) Member of the German Center for Lung Research (DZL) Giessen Germany

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 March 2024 in Chest
Verified
Journal Article
Open access
AYAthiththan Yogeswaran
Athiththan Yogeswaran
HGHenning Gall
Henning Gall
MFMeike Fünderich
Meike Fünderich
MWMartin R. Wilkins
Martin R. Wilkins
LHLuke Howard
Luke Howard
AVAndreea Varga
Andreea Varga
Pulmonary hypertension (PH) is a heterogeneous disease with a poor prognosis. Accurate risk stratification is essential for guiding treatment decisions in pulmonary arterial hypertension (PAH). Although various risk models have been developed for PAH, their comparative prognostic potential requires further exploration. Additionally, the applicability of risk scores in PH groups beyond group 1 remains to be investigated. Are risk scores originally developed for PAH predictive in PH groups 1 through 4? We conducted a comprehensive analysis of outcomes among patients with incident PH enrolled in the multicenter worldwide Pulmonary Vascular Research Institute GoDeep meta-registry. Analyses were performed across PH groups 1 through 4 and further subgroups to evaluate the predictive value of PAH risk scores, including the Registry to Evaluate Early and Long-Term PAH Disease Mangement (REVEAL) Lite 2, REVEAL 2.0, European Society of Cardiology/European Respiratory Society 2022, Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA) 3-strata, and COMPERA 4-strata. Eight thousand five hundred sixty-five patients were included in the study, of whom 3,537 patients were assigned to group 1 PH, whereas 1,807 patients, 1,635 patients, and 1,586 patients were assigned to group 2 PH, group 3 PH, and group 4 PH, respectively. Pulmonary hemodynamics were impaired with median mean pulmonary arterial pressure of 42 mm Hg (interquartile range, 33-52 mm Hg) and pulmonary vascular resistance of 7 Wood units (WU) (interquartile range, 4-11 WU). All risk scores were prognostic in the entire PH population and in each of the PH groups 1 through 4. The REVEAL scores, when used as continuous prediction models, demonstrated the highest statistical prognostic power and granularity; the COMPERA 4-strata risk score provided subdifferentiation of the intermediate-risk group. Similar results were obtained when separately analyzing various subgroups (PH subgroups 1.1, 1.4.1, and 1.4.4; PH subgroups 3.1 and 3.2; group 2 with isolated postcapillary PH vs combined precapillary and postcapillary PH; patients of all groups with concomitant cardiac comorbidities; and severe [> 5 WU] vs nonsevere PH). This comprehensive study with real-world data from 15 PH centers showed that PAH-designed risk scores possess predictive power in a large PH cohort, whether considered as common to the group or calculated separately for each PH group (1-4) and various subgroups. ClinicalTrials.gov; No.: NCT05329714; URL: www. gov.


1 March 2021 in The Lancet Planetary Health
Verified
Journal Article
Open access
NPNicole de Paula
Nicole de Paula
LJLaura Jung
Laura Jung
KMKathleen Mar
Kathleen Mar
KBKathryn Bowen
Kathryn Bowen
MMMariam Maglakelidze
Mariam Maglakelidze
SGSophie Gepp
Sophie Gepp

8 July 2025 in Pulmonary Circulation
Verified
Journal Article
Open access
AJArun Jose
Arun Jose
AYAthiththan Yogeswaran
Athiththan Yogeswaran
MFMeike Fuenderich
Meike Fuenderich
DKDavid Gerard Kiely
David Gerard Kiely
ASAndrew J. Sweatt
Andrew J. Sweatt
TPthe PVRI‐GoDeep‐Consortium
the PVRI‐GoDeep‐Consortium
Portopulmonary hypertension (PoPH), a type of pulmonary arterial hypertension (PAH) in patients with liver disease, is associated with high morbidity and mortality. The relationship between cardiopulmonary hemodynamics, PAH therapy, and survival in PoPH remains unclear. We performed a retrospective cohort study of PoPH patients from the international pulmonary hypertension (PH) meta‐registry, PVRI GoDeep. PAH was defined by a mean pulmonary arterial pressure > 20 mmHg, pulmonary arterial wedge pressure ≤ 15 mmHg, and a pulmonary vascular resistance (PVR) > 2 Wood Units. PoPH diagnoses were assigned by each center's PH specialist based on international guidelines at the time of enrollment. 246 incident PoPH patients met eligibility criteria and were included in the analysis, equally split between males (51%) and females (49%), with a median age of 54 years. When compared to both patients with IPAH and those with other subtypes of PAH (not classified as PoPH or IPAH), those with PoPH had significantly lower 5‐year survival rates (46% vs. 68% vs. 65%, log‐rank p < 0.001). Amongst the PoPH patients, however, there was no significant difference in 5‐year survival when dichotomized by disease severity, either by a PVR of 5 Wood Units or a CI of 2.5 L/min/m2. Treatment of the PoPH patients with PAH‐targeted therapies was associated with significantly higher 5‐year survival rates compared to those not receiving such treatments, as shown by Kaplan–Meier analysis. This survival benefit was observed for PDE5i (50% vs. 34%, log‐rank p = 0.029), ERA (58% vs. 34%, log‐rank p < 0.001), and the combination of PDE5i and/or ERA (51% vs. 22%, log‐rank p < 0.001), as well as any PAH‐targeting treatment (50% vs. 26%, log‐rank p = 0.007). Corresponding survival advantage was noted when including only PoPH patients with MELD Score ≥ 13. PoPH is a disease with significantly worse long‐term survival than other PAH subtypes, but targeted PAH therapy is associated with a robust survival benefit. Survival did not differ across high‐risk PVR and cardiac index thresholds, suggesting the factors that influence prognosis and survival in PoPH may be unique as compared to other PAH subtypes, and warrant further investigation.

27 September 2024 in ERJ Open Research
Verified
Journal Article
Open access
PDF file
AYAthiththan Yogeswaran
Athiththan Yogeswaran
MFMeike Fünderich
Meike Fünderich
HOHorst Olschewski
Horst Olschewski
GKGabor Kovacs
Gabor Kovacs
DKDavid Gerard Kiely
David Gerard Kiely
KTKhodr Tello
Khodr Tello
Introduction: . Pulmonary hypertension (PH) definition was recently changed and led to a new subset of PH patients with mildly impaired pulmonary hemodynamics, characterized by a mean pulmonary artery pressure of 21–24 mmHg and with a pulmonary vascular resistance >2Wood Units. We evaluated the association of PH-targeted therapy and outcome in mild precapillary PH using the PVRI GoDeep meta-registry.Methods: . All patients with mild precapillary PH (mPAP 21–24 mmHg, PAWP ≤15 mmHg, PVR >2WU) diagnosed with PAH and CTEPH were enrolled. Patients were considered treated if PH-targeted therapy was initiated within 6 months of diagnostic right heart catheterization. Various statistical models, including in-depth sensitivity analyses, were used to examine the association between PH-targeted therapy and transplant-free survival.Results: . 132 patients with group 1 or group 4 mild PH were identified, of whom 34 patients received PH-targeted therapy. There were no differences in baseline hemodynamics between untreated and treated groups, while treated patients suffered more frequently from renal comorbidities and required long-term oxygen treatment more often. Most prescribed were phosphodiesterase-5-inhibitors. PH-targeted therapy was associated with significantly higher survival rates, compared to those without treatment. Cox-regression analysis revealed significantly reduced hazard ratios among treated patients in Cox-regression analyses adjusted for various confounders. Subgroup analyses in PAH (n=78) similarly indicated higher survival rates and reduced hazard ratios in treated patients.Conclusion: . PH-targeted therapy may be associated with improved survival in PAH and CTEPH patients with mild PH. To mitigate potential bias of the results due to the retrospective study design, randomized controlled trials are warranted.

26 August 2026 in Chest
Verified
Journal Article
Open access
AYAthiththan Yogeswaran
Athiththan Yogeswaran
MFMeike Fünderich
Meike Fünderich
DKDavid G. Kiely
David G. Kiely
JAJeffrey S. Annis
Jeffrey S. Annis
EBEvan Brittain
Evan Brittain
NZNayeli Zayas
Nayeli Zayas